目的 探究血脂康膠囊聯(lián)合依那普利和硝苯地平治療高血壓合并冠心病的臨床療效。方法 收集2014年1月—2015年1月于海南省萬寧市人民醫(yī)院就診的高血壓合并冠心病患者100例,根據(jù)治療方案的不同分為對照組和治療組,每組各50例。對照組口服硝苯地平控釋片,1片/次,1次/d,口服馬來酸依那普利片,初始劑量為1片/次,1次/d,2周后1片/次,2次/d。治療組在對照組的基礎(chǔ)上口服血脂康膠囊,2粒/次,2次/d。兩組患者均連續(xù)治療2個月。觀察兩組的臨床療效,比較兩組治療前后血壓、血脂的變化情況。結(jié)果 治療后,對照組和治療組的降壓總有效率分別為80.0%、92.0%;兩組降脂總有效率分別為80.0%、94.0%;兩組心電圖總有效率分別為76.0%、88.0%;兩組心絞痛總有效率分別為74.0%、90.0%,兩組總有效率比較差異具有統(tǒng)計學(xué)意義(P<0.05)。治療后,兩組患者收縮壓、舒張壓、總膽固醇(TC)、三酰甘油(TG)、低密度脂蛋白膽固醇(LDL-C)均顯著降低,高密度脂蛋白膽固醇(HDL-C)顯著升高,同組治療前后差異具有統(tǒng)計學(xué)意義(P<0.05);且治療組這些觀察指標的改善程度優(yōu)于對照組,兩組比較差異具有統(tǒng)計學(xué)意義(P<0.05)。結(jié)論 血脂康膠囊聯(lián)合依那普利和硝苯地平治療高血壓合并冠心病患者的臨床療效確切,安全性高,能夠有效改善患者的血壓及血脂情況,具有一定的臨床推廣應(yīng)用價值。

Objective To explore the clinical effect of Xuezhikang Capsules combined with enalapril and nifedipine in treatment of hypertension with coronary heart disease. Methods Patients (100 cases) with hypertension with coronary heart disease in People's Hospital of Wanning in Hainan Province from January 2014 to January 2015 were enrolled in this study. According to the different treatment plans, patients were divided into treatment group (50 cases) and control group (50 cases). The patients in the control group were po administered with Nifedipine Controlled Release Tablets, 1 tablet/time, once daily. And they were po administered with Enalapril Maleate Tablets, initial dosage was 1 tablet/time, once daily, after 2 weeks the dosage was 1 tablet/time, twice daily. The patients in the treatment group were po administered with Xuezhikang Capsules on the basis of control group, 2 grains/time, twice daily. The patients in two groups were treated for 2 months. After treatment, the clinical efficacy was evaluated, and the changes of blood pressure and blood lipid in two groups were compared. Results After treatment, the depressurization efficacies in the control and treatment groups were 80.0% and 92.0%, respectively; The lipid-decreasing efficacies in the control and treatment groups were 80.0% and 94.0%, respectively; Electrocardiogram total effective rate in two groups were 76.0% and 88.0%, respectively; Angina total effective rate in two groups were 74.0% and 90.0%, respectively, and there were differences between two groups (P < 0.05). After treatment, systolic pressure, diastolic blood pressure, TC, TG, and LDL-C in two groups were significantly decreased, but HDL-C was significantly increased, and the difference was statistically significant in the same group (P < 0.05). After treatment, the observational in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Xuezhikang Capsule combined with enalapril and nifedipine has clinical curative effect with high safety, and can effectively improve the blood pressure and blood lipid of patients, which has a certain clinical application value.